Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.

Rujas E, Leaman DP, Insausti S, Ortigosa-Pascual L, Zhang L, Zwick MB, Nieva JL.

J Virol. 2018 Mar 28;92(8). pii: e02249-17. doi: 10.1128/JVI.02249-17. Print 2018 Apr 15.

2.

Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Gift SK, Leaman DP, Zhang L, Kim AS, Zwick MB.

J Virol. 2017 Nov 30;91(24). pii: e01216-17. doi: 10.1128/JVI.01216-17. Print 2017 Dec 15.

3.

Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses.

Bale S, Goebrecht G, Stano A, Wilson R, Ota T, Tran K, Ingale J, Zwick MB, Wyatt RT.

J Virol. 2017 Jul 27;91(16). pii: e00443-17. doi: 10.1128/JVI.00443-17. Print 2017 Aug 15.

4.

Dense Array of Spikes on HIV-1 Virion Particles.

Stano A, Leaman DP, Kim AS, Zhang L, Autin L, Ingale J, Gift SK, Truong J, Wyatt RT, Olson AJ, Zwick MB.

J Virol. 2017 Jun 26;91(14). pii: e00415-17. doi: 10.1128/JVI.00415-17. Print 2017 Jul 15.

5.

High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.

Ingale J, Stano A, Guenaga J, Sharma SK, Nemazee D, Zwick MB, Wyatt RT.

Cell Rep. 2016 May 31;15(9):1986-99. doi: 10.1016/j.celrep.2016.04.078. Epub 2016 May 19.

6.

Trimerization of the HIV Transmembrane Domain in Lipid Bilayers Modulates Broadly Neutralizing Antibody Binding.

Reichart TM, Baksh MM, Rhee JK, Fiedler JD, Sligar SG, Finn MG, Zwick MB, Dawson PE.

Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2688-92. doi: 10.1002/anie.201508421. Epub 2016 Jan 22.

7.

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.

Lee JH, Leaman DP, Kim AS, Torrents de la Peña A, Sliepen K, Yasmeen A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick MB, Wilson IA, Ward AB.

Nat Commun. 2015 Sep 25;6:8167. doi: 10.1038/ncomms9167.

8.

Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Leaman DP, Lee JH, Ward AB, Zwick MB.

J Virol. 2015 Jul;89(13):6725-45. doi: 10.1128/JVI.03738-14. Epub 2015 Apr 15.

9.

Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization.

Kim AS, Leaman DP, Zwick MB.

PLoS Pathog. 2014 Jul 24;10(7):e1004271. doi: 10.1371/journal.ppat.1004271. eCollection 2014 Jul.

10.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR.

Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

11.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

12.

Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.

Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D.

J Immunol. 2013 Sep 15;191(6):3186-3191. doi: 10.4049/jimmunol.1301285. Epub 2013 Aug 12.

13.

Increased functional stability and homogeneity of viral envelope spikes through directed evolution.

Leaman DP, Zwick MB.

PLoS Pathog. 2013 Feb;9(2):e1003184. doi: 10.1371/journal.ppat.1003184. Epub 2013 Feb 28.

14.

Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.

Narayan KM, Agrawal N, Du SX, Muranaka JE, Bauer K, Leaman DP, Phung P, Limoli K, Chen H, Boenig RI, Wrin T, Zwick MB, Whalen RG.

PLoS One. 2013;8(1):e52732. doi: 10.1371/journal.pone.0052732. Epub 2013 Jan 9.

15.

Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules.

Gach JS, Leaman DP, Zwick MB.

Curr Top Med Chem. 2011 Dec;11(24):2997-3021. Review.

PMID:
22044228
16.

Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA.

J Mol Biol. 2011 Dec 2;414(3):460-76. doi: 10.1016/j.jmb.2011.10.014. Epub 2011 Oct 15.

17.

Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1).

Agrawal N, Leaman DP, Rowcliffe E, Kinkead H, Nohria R, Akagi J, Bauer K, Du SX, Whalen RG, Burton DR, Zwick MB.

PLoS One. 2011;6(6):e21339. doi: 10.1371/journal.pone.0021339. Epub 2011 Jun 27.

18.

A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein.

Du SX, Xu L, Zhang W, Tang S, Boenig RI, Chen H, Mariano EB, Zwick MB, Parren PW, Burton DR, Wrin T, Petropoulos CJ, Ballantyne JA, Chambers M, Whalen RG.

PLoS One. 2011;6(6):e20927. doi: 10.1371/journal.pone.0020927. Epub 2011 Jun 29.

19.

Synthesis and analysis of the membrane proximal external region epitopes of HIV-1.

Ingale S, Gach JS, Zwick MB, Dawson PE.

J Pept Sci. 2010 Dec;16(12):716-22. doi: 10.1002/psc.1325.

PMID:
21104968
20.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

21.

A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.

Murray EJ, Leaman DP, Pawa N, Perkins H, Pickford C, Perros M, Zwick MB, Butler SL.

J Virol. 2010 Jul;84(14):7288-99. doi: 10.1128/JVI.00535-10. Epub 2010 Apr 28.

22.

4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.

Nakamura KJ, Gach JS, Jones L, Semrau K, Walter J, Bibollet-Ruche F, Decker JM, Heath L, Decker WD, Sinkala M, Kankasa C, Thea D, Mullins J, Kuhn L, Zwick MB, Aldrovandi GM.

PLoS One. 2010 Mar 23;5(3):e9786. doi: 10.1371/journal.pone.0009786.

23.

In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Leaman DP, Kinkead H, Zwick MB.

J Virol. 2010 Apr;84(7):3382-95. doi: 10.1128/JVI.02363-09. Epub 2010 Jan 20.

24.

Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.

Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1529-34. doi: 10.1073/pnas.0909680107. Epub 2010 Jan 4.

25.

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, Kwong PD.

J Virol. 2010 Mar;84(6):2955-62. doi: 10.1128/JVI.02257-09. Epub 2009 Dec 30.

26.

A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, Burton DR, Zwick MB, Wilson IA.

J Virol. 2009 Sep;83(17):8451-62. doi: 10.1128/JVI.00685-09. Epub 2009 Jun 10.

27.

Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.

Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, Reinherz EL, Wagner G, Kim M.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9057-62. doi: 10.1073/pnas.0901474106. Epub 2009 May 19.

28.

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.

Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, Kaizu M, Soma T, León EJ, MacNair C, Leaman DP, Zwick MB, Gostick E, Musani SK, Price DA, Friedrich TC, Rakasz EG, Wilson NA, McDermott AB, Boyle R, Allison DB, Burton DR, Koff WC, Watkins DI.

J Exp Med. 2008 Oct 27;205(11):2537-50. doi: 10.1084/jem.20081524. Epub 2008 Oct 6.

29.

A welcome burst of human antibodies.

Zwick MB, Gach JS, Burton DR.

Nat Biotechnol. 2008 Aug;26(8):886-7. doi: 10.1038/nbt0808-886. No abstract available.

PMID:
18688242
30.

Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, Hoxie JA, Robinson JE, Moore PL, Binley JM.

Virology. 2008 Aug 1;377(2):364-78. doi: 10.1016/j.virol.2008.04.045. Epub 2008 Jun 9.

31.

Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, Maruyama T, Bewley CA, Bowdish K, Clore GM, Dawson PE, Frederickson S, Mage RG, Richman DD, Burton DR, Zwick MB.

Virology. 2008 Jul 20;377(1):170-83. doi: 10.1016/j.virol.2008.04.005. Epub 2008 May 21.

32.

Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.

Scherer EM, Zwick MB, Teyton L, Burton DR.

AIDS. 2007 Oct 18;21(16):2131-9.

PMID:
18090039
33.

HIV-1 neutralization: mechanisms and relevance to vaccine design.

Zwick MB, Burton DR.

Curr HIV Res. 2007 Nov;5(6):608-24. Review.

PMID:
18045117
34.

Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.

Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PW, Burton DR, Scott JK, Wilson IA.

J Mol Biol. 2007 Jun 8;369(3):696-709. Epub 2007 Jan 27.

35.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.

Nature. 2007 Feb 15;445(7129):732-7.

36.

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.

J Virol. 2007 Apr;81(8):4033-43. Epub 2007 Feb 7.

37.
38.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

39.

Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.

van Houten NE, Zwick MB, Menendez A, Scott JK.

Vaccine. 2006 May 8;24(19):4188-200. Epub 2006 Jan 11.

40.

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM.

J Virol. 2006 Mar;80(5):2515-28.

41.

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE.

J Virol. 2006 Feb;80(4):1680-7.

42.

The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.

Zwick MB.

AIDS. 2005 Nov 4;19(16):1725-37. No abstract available.

PMID:
16227780
43.

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA.

Immunity. 2005 Feb;22(2):163-73.

44.

Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response.

Ho J, Uger RA, Zwick MB, Luscher MA, Barber BH, MacDonald KS.

Vaccine. 2005 Feb 18;23(13):1559-73.

PMID:
15694508
45.
46.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

47.

The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.

Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, Kunert R, Katinger H, Wilson IA, Burton DR.

J Virol. 2004 Mar;78(6):3155-61.

48.

gp41: HIV's shy protein.

Zwick MB, Saphire EO, Burton DR.

Nat Med. 2004 Feb;10(2):133-4. No abstract available.

PMID:
14760422
49.

Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design.

Saphire EO, Stanfield RL, Crispin MD, Morris G, Zwick MB, Pantophlet RA, Parren PW, Rudd PM, Dwek RA, Burton DR, Wilson IA.

Adv Exp Med Biol. 2003;535:55-66. Review. No abstract available.

PMID:
14714888
50.

Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.

Zhang MY, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS.

J Mol Biol. 2004 Jan 2;335(1):209-19.

PMID:
14659751

Supplemental Content

Loading ...
Support Center